Cowen slashes price target on Clover Health Investments Corp. [CLOV] – find out why.


Clover Health Investments Corp. [NASDAQ: CLOV] stock went on an upward path that rose over 0.36% on Monday, amounting to a one-week price increase of more than 6.18%. The company report on May 9, 2022 that Clover Health Reports First Quarter 2022 Financial Results.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


First quarter total revenue was $874.4 million, compared to $200.3 million in first quarter 2021.

Lives under Clover Management grew to ~257,000 from ~66,000 year-over-year.

Over the last 12 months, CLOV stock dropped by -60.26%. The one-year Clover Health Investments Corp. stock forecast points to a potential upside of 31.25. The average equity rating for CLOV stock is currently 3.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.32 billion, with 473.03 million shares outstanding and 339.26 million shares in the current float. Compared to the average trading volume of 12.53M shares, CLOV stock reached a trading volume of 7413398 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Clover Health Investments Corp. [CLOV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for Clover Health Investments Corp. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 02, 2022. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on February 02, 2022, representing the official price target for Clover Health Investments Corp. stock. Previously, the target price had yet another raise to $3, while SVB Leerink analysts kept a Mkt Perform rating on CLOV stock. On January 10, 2022, analysts decreased their price target for CLOV shares from 9 to 3.50.

The Average True Range (ATR) for Clover Health Investments Corp. is set at 0.25, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 0.62. The Price to Book ratio for the last quarter was 2.64, with the Price to Cash per share for the same quarter was set at 1.20.

CLOV Stock Performance Analysis:

Clover Health Investments Corp. [CLOV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.18. With this latest performance, CLOV shares dropped by -0.72% in over the last four-week period, additionally sinking by -52.17% over the last 6 months – not to mention a drop of -60.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 49.91, with the RSI for the last a single of trading hit 53.31, and the three-weeks RSI is set at 48.50 for Clover Health Investments Corp. [CLOV]. The present Moving Average for the last 50 days of trading for this stock 3.02, while it was recorded at 2.76 for the last single week of trading, and 4.97 for the last 200 days.

Insight into Clover Health Investments Corp. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Clover Health Investments Corp. [CLOV] shares currently have an operating margin of -37.11. Clover Health Investments Corp.’s Net Margin is presently recorded at -38.21.

Return on Equity for this stock declined to -88.46, with Return on Assets sitting at -65.05.

Clover Health Investments Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.20.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp. go to 19.10%.

Clover Health Investments Corp. [CLOV] Insider Position Details

There are presently around $273 million, or 26.70% of CLOV stock, in the hands of institutional investors. The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 26,087,528, which is approximately 0.773% of the company’s market cap and around 1.30% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 7,787,680 shares of the stock with an approximate value of $21.34 million in CLOV stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $20.04 million in CLOV stock with ownership of nearly 44.779% of the company’s market capitalization.

Positions in Clover Health Investments Corp. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 94 institutional holders increased their position in Clover Health Investments Corp. [NASDAQ:CLOV] by around 15,003,085 shares. Additionally, 65 investors decreased positions by around 45,220,840 shares, while 44 investors held positions by with 39,386,944 shares. The mentioned changes placed institutional holdings at 99,610,869 shares, according to the latest SEC report filing. CLOV stock had 43 new institutional investments in for a total of 4,907,507 shares, while 33 institutional investors sold positions of 34,602,452 shares during the same period.